Pfizer on Friday said its drug for an advanced form of lung cancer showed promising long-term results in a late-stage trial, which could help establish it as the new standard treatment for the condition.
Around 60% of patients treated with Lorbrena were alive without seeing their cancer progress after that same period. That compares to 8% among those who took Xalkori. He noted that there are no head-to-head trials that compare Pfizer's Lorbrena with competing lung cancer drugs, including one called alectinib and another called brigatinib.
Lorbrena slashed the risk of the cancer progressing in the brain by 94% compared to Pfizer's old drug. Only four of the 114 patients taking Lorbrena developed brain metastases within about 16 months, compared to 39 out of the 109 taking Xalkori. No new safety issues were reported for Lorbrena. The most common side effects included swelling, weight gain, cognition and mood changes and high cholesterol in the blood, among others.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: chicagotribune - 🏆 8. / 91 Read more »